SG11201700816YA - Crystal forms of glutaminase inhibitors - Google Patents
Crystal forms of glutaminase inhibitorsInfo
- Publication number
- SG11201700816YA SG11201700816YA SG11201700816YA SG11201700816YA SG11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA
- Authority
- SG
- Singapore
- Prior art keywords
- crystal forms
- glutaminase inhibitors
- glutaminase
- inhibitors
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462034547P | 2014-08-07 | 2014-08-07 | |
PCT/US2015/044301 WO2016022969A1 (fr) | 2014-08-07 | 2015-08-07 | Formes cristallines d'inhibiteurs de glutaminase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700816YA true SG11201700816YA (en) | 2017-02-27 |
Family
ID=55264662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700816YA SG11201700816YA (en) | 2014-08-07 | 2015-08-07 | Crystal forms of glutaminase inhibitors |
Country Status (13)
Country | Link |
---|---|
US (2) | US10316030B2 (fr) |
EP (1) | EP3193876B1 (fr) |
JP (3) | JP6889101B2 (fr) |
KR (1) | KR20170082494A (fr) |
CN (1) | CN106999490A (fr) |
AU (2) | AU2015300825B2 (fr) |
BR (1) | BR112017002403A2 (fr) |
CA (1) | CA2957225A1 (fr) |
EA (1) | EA037738B1 (fr) |
IL (1) | IL250391B (fr) |
MX (1) | MX2017001620A (fr) |
SG (1) | SG11201700816YA (fr) |
WO (1) | WO2016022969A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2420497T3 (pl) | 2006-09-26 | 2016-06-30 | Celgene Corp | 5-Podstawione pochodne chinazolinonu jako środki przeciwnowotworowe |
PE20140983A1 (es) | 2011-03-11 | 2014-08-25 | Celgene Corp | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos |
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
HRP20211610T1 (hr) | 2012-11-16 | 2022-02-04 | Calithera Biosciences, Inc. | Inhibitori heterocikličke glutaminaze |
EP3154590B1 (fr) | 2014-06-13 | 2021-04-14 | Calithera Biosciences, Inc. | Traitement combiné avec des inhibiteurs de glutaminase |
JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
SG11201708034SA (en) * | 2015-03-30 | 2017-10-30 | Calithera Biosciences Inc | Methods of administering glutaminase inhibitors |
MX2017012824A (es) | 2015-04-06 | 2018-05-15 | Calithera Biosciences Inc | Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. |
AU2016335991A1 (en) | 2015-10-05 | 2018-05-10 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
EP3503886A4 (fr) | 2016-08-25 | 2020-07-22 | Calithera Biosciences, Inc. | Polythérapie comprenant des inhibiteurs de glutaminase |
WO2018039441A1 (fr) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Traitement combiné avec des inhibiteurs de glutaminase. |
WO2019089854A1 (fr) * | 2017-10-31 | 2019-05-09 | President And Fellows Of Harvard College | Procédés et compositions pour traiter la leucémie myéloïde aigue |
US20220153780A1 (en) * | 2019-03-26 | 2022-05-19 | Tonix Pharma Holdings Limited | Salt forms of s-(n, n-diethylcarbamoyl)glutathione |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1019519A (en) | 1911-07-11 | 1912-03-05 | Oscar Martin Polin | Apparatus for making backing for teeth. |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な(−)−ビュープロピオンの薬学的使用 |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
PL1654002T5 (pl) | 2003-08-07 | 2014-06-30 | Allergan Inc | Kompozycje do dostarczania środków terapeutycznych do oczu |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
AU2005245785B2 (en) | 2004-04-15 | 2011-04-07 | Banyan Biomarkers Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
ES2361584T3 (es) | 2006-09-15 | 2011-06-20 | Celgene Corporation | Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos. |
CA2694136C (fr) | 2007-08-02 | 2013-09-17 | Amgen Inc. | Modulateur de la pi3 kinase et leurs procedes d'utilisation |
WO2009104696A1 (fr) | 2008-02-19 | 2009-08-27 | 株式会社アーネストメディスン | Composition orale ou entérale utile pour la récupération de fonctions physiques |
WO2010093434A1 (fr) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues de lénalidomide |
EP2396313A1 (fr) | 2009-02-11 | 2011-12-21 | Celgene Corporation | Isotopologues de la thalidomide |
LT3202460T (lt) | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
JP2013543009A (ja) | 2010-11-18 | 2013-11-28 | デューテリア ファーマシューティカルズ, インコーポレイテッド | 3−ジュウテロ−ポマリドマイド |
US9045417B2 (en) | 2011-01-14 | 2015-06-02 | Celgene Corporation | Isotopologues of isoindole derivatives |
CA2742342A1 (fr) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine |
FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
JP5712882B2 (ja) * | 2011-09-28 | 2015-05-07 | 株式会社豊田自動織機 | 電動圧縮機用の電動モータ |
CN103030597B (zh) | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 |
JP6031527B2 (ja) * | 2011-11-21 | 2016-11-24 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼのヘテロ環式阻害剤 |
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
CA2874521A1 (fr) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Ciblage de la voie allant de la glutamine au pyruvate pour traiter un cancer associe a l'oncogene kras |
CA2884103A1 (fr) | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methodes pour le traitement du cancer du sein localement avance |
WO2014043633A1 (fr) | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Utilisation de e-cadhérine et de vimentine pour la sélection de patients répondant à un traitement |
HRP20211610T1 (hr) | 2012-11-16 | 2022-02-04 | Calithera Biosciences, Inc. | Inhibitori heterocikličke glutaminaze |
BR112015011756A2 (pt) | 2012-11-21 | 2017-07-11 | Agios Pharmaceuticals Inc | inibidores da glutamase e métodos de uso |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014079011A1 (fr) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Composés hétérocycliques pour inhiber la glutaminase et procédés d'utilisation de ceux-ci |
JP6285950B2 (ja) * | 2012-12-03 | 2018-02-28 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼの複素環式阻害剤を用いるがんの処置 |
WO2015061432A1 (fr) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Traitement d'infections virales avec des inhibiteurs de glutaminase |
WO2015138902A1 (fr) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Polythérapie avec des inhibiteurs de glutaminase |
US10221459B2 (en) | 2014-05-13 | 2019-03-05 | Case Western Reserve University | Compositions and methods of treating cancer harboring PIKC3A mutations |
EP3154590B1 (fr) | 2014-06-13 | 2021-04-14 | Calithera Biosciences, Inc. | Traitement combiné avec des inhibiteurs de glutaminase |
WO2016004418A1 (fr) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Thérapie par inhibiteur de glutaminase |
WO2016014890A1 (fr) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Traitement du myélome multiple avec des inhibiteurs hétérocycliques de la glutaminase |
JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
WO2016054388A1 (fr) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibiteurs de glutaminase |
WO2016077632A2 (fr) | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition du catabolisme de la proline pour le traitement du cancer et d'autres applications thérapeutiques |
SG11201708034SA (en) | 2015-03-30 | 2017-10-30 | Calithera Biosciences Inc | Methods of administering glutaminase inhibitors |
MX2017012824A (es) | 2015-04-06 | 2018-05-15 | Calithera Biosciences Inc | Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. |
AU2016335991A1 (en) | 2015-10-05 | 2018-05-10 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
WO2018039441A1 (fr) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Traitement combiné avec des inhibiteurs de glutaminase. |
WO2018039442A1 (fr) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Traitement du cancer avec des inhibiteurs de glutaminase |
EP3503886A4 (fr) | 2016-08-25 | 2020-07-22 | Calithera Biosciences, Inc. | Polythérapie comprenant des inhibiteurs de glutaminase |
JP2020510032A (ja) | 2017-03-10 | 2020-04-02 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼ阻害剤との併用療法 |
-
2015
- 2015-08-07 JP JP2017506401A patent/JP6889101B2/ja active Active
- 2015-08-07 CN CN201580054339.2A patent/CN106999490A/zh active Pending
- 2015-08-07 MX MX2017001620A patent/MX2017001620A/es unknown
- 2015-08-07 EA EA201790337A patent/EA037738B1/ru not_active IP Right Cessation
- 2015-08-07 EP EP15830024.4A patent/EP3193876B1/fr active Active
- 2015-08-07 KR KR1020177006199A patent/KR20170082494A/ko not_active Application Discontinuation
- 2015-08-07 CA CA2957225A patent/CA2957225A1/fr not_active Abandoned
- 2015-08-07 SG SG11201700816YA patent/SG11201700816YA/en unknown
- 2015-08-07 BR BR112017002403A patent/BR112017002403A2/pt not_active Application Discontinuation
- 2015-08-07 AU AU2015300825A patent/AU2015300825B2/en not_active Ceased
- 2015-08-07 US US15/501,622 patent/US10316030B2/en not_active Expired - Fee Related
- 2015-08-07 WO PCT/US2015/044301 patent/WO2016022969A1/fr active Application Filing
-
2017
- 2017-02-01 IL IL250391A patent/IL250391B/en unknown
-
2019
- 2019-06-07 US US16/434,872 patent/US10676472B2/en active Active
- 2019-11-18 JP JP2019208032A patent/JP2020037588A/ja active Pending
- 2019-12-31 AU AU2019284149A patent/AU2019284149A1/en not_active Abandoned
-
2021
- 2021-06-30 JP JP2021108805A patent/JP2021165286A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2015300825A1 (en) | 2017-03-09 |
EA201790337A1 (ru) | 2017-09-29 |
US20170226101A1 (en) | 2017-08-10 |
CA2957225A1 (fr) | 2016-02-11 |
US20190359607A1 (en) | 2019-11-28 |
EP3193876A1 (fr) | 2017-07-26 |
JP2017523991A (ja) | 2017-08-24 |
JP6889101B2 (ja) | 2021-06-18 |
CN106999490A (zh) | 2017-08-01 |
AU2015300825B2 (en) | 2019-10-10 |
US10316030B2 (en) | 2019-06-11 |
JP2020037588A (ja) | 2020-03-12 |
EP3193876A4 (fr) | 2017-12-27 |
IL250391A0 (en) | 2017-03-30 |
WO2016022969A1 (fr) | 2016-02-11 |
KR20170082494A (ko) | 2017-07-14 |
IL250391B (en) | 2021-10-31 |
AU2019284149A1 (en) | 2020-01-30 |
MX2017001620A (es) | 2017-05-10 |
EP3193876B1 (fr) | 2022-01-12 |
BR112017002403A2 (pt) | 2017-12-05 |
EA037738B1 (ru) | 2021-05-17 |
US10676472B2 (en) | 2020-06-09 |
JP2021165286A (ja) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201604272B (en) | Inhibitors of glutaminase | |
IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
HK1255427A1 (zh) | 一種lsd1抑制劑的鹽 | |
IL250391B (en) | Crystalline forms of glutaminase inhibitors | |
IL246902A0 (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
GB2542881B (en) | Crystal forms of ß-nicotinamide mononucleotide | |
IL249476A0 (en) | Combined treatment with glutaminase inhibitors | |
ZA201700304B (en) | Spirocycloheptanes as inhibitors of rock | |
FI3371171T3 (fi) | Ret:n estäjiä | |
HK1254129A1 (zh) | 給予谷氨酰胺酶抑制劑的方法 | |
GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
IL273463A (en) | Crystalline forms of immunomodulators | |
GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
IL253018A0 (en) | Crystalline forms of apomorphine and their uses | |
GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
EP3212611A4 (fr) | Formes cristallines de chlorhydrate de vérapamil | |
EP3164195A4 (fr) | Thérapie par inhibiteur de glutaminase | |
GB201421812D0 (en) | New therapeutic uses of enzyme inhibitors | |
GB201410529D0 (en) | New therapeutic uses of enzyme inhibitors |